Afficher la couverture 'Phase II Study Evaluating the Mechanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR-mutated Non-pretreated Advanced Lung Cancer Receiving Osimertinib Until and Beyond Radiologic Progression: The MELROSE Trial | Bennouna, Jaafar' en grand format
/5

0 avis

Phase II Study Evaluating the Mechanisms of Resistance on Tumor Tissue and Liquid Biopsy in Patients With EGFR-mutated Non-pretreated Advanced Lung Cancer Receiving Osimertinib Until and Beyond Radiologic Progression: The MELROSE Trial

Archive ouverte

Bennouna, Jaafar | Girard, Nicolas | Audigier-Valette, Clarisse | Le Thuaut, Aurélie | Gervais, Radj | Masson, Philippe | Marcq, Marie | Molinier, Olivier | Cortot, Alexis | Debieuvre, Didier | Cadranel, Jacques | Lena, Hervé | Moro-Sibilot, Denis | Chouaid, Christos | Mennecier, Bertrand | Urban, Thierry | Sagan, Christine | Perrier, Ludivine | Barlesi, Fabrice | Denis, Marc

Edité par CCSD ; Elsevier -

International audience. Osimertinib, a third-generation tyrosine kinase inhibitor, is a new therapeutic option in epidermal growth factor receptor (EGFR)-mutated non-pretreated advanced non-small-cell lung cancer (NSCLC). The tumor escape mechanisms after first-line treatment with osimertinib are partially known; most of the data being obtained by analysis of circulating tumor DNA (ctDNA) from the FLAURA phase III trial.

Consulter en ligne

Suggestions

Du même auteur

Real-life experience of ceritinib in crizotinib-pretreatedadvanced non-small cell lung cancer patients

Archive ouverte | Cadranel, Jacques | CCSD

International audience. Here we report our experience of ceritinib in crizotinib-pretreated patients with anaplastic lymphoma kinase () positive () non-small cell lung cancer (NSCLC) in a French temporary authorisat...

Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial

Archive ouverte | Scherpereel, Arnaud | CCSD

International audience. There is no recommended therapy for malignant pleural mesothelioma that has progressed after first-line pemetrexed and platinum-based chemotherapy. Disease control has been less than 30% in a...

Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial

Archive ouverte | Scherpereel, Arnaud | CCSD

International audience

Chargement des enrichissements...